SET and acute myeloid leukemia: Because the efficacy of peptide SET inhibitor OP449 was only confirmed in mice xenografted with drug-sensitive human acute myeloid leukemia HL-60 cells [29], ponatinib, the only therapeutic agent for T315I mutation of CML patients, was chosen as a positive control for the comparison of in vivo efficacy.